🔴 Arcturus Therapeutics is trading 5% down with no clear catalyst identified

Arcturus Therapeutics is trading at $13.73, down 5.05%, with no clear company-specific catalyst identified for the September 29 decline.

• The latest major company update was September 23, reporting interim Phase 2 ARCT-810 results and introducing the LUNAR 2.0 platform.
• Arcturus Therapeutics was scheduled to participate in an investor conference on September 29, but available reporting does not link it to the share move.
• Major indices were mixed, with no broad same-direction move above 0.5%.